Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1036 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Vancomycin Study is a multi-center, prospective randomized controlled trial that will compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder at the time of fracture fixation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures

NCT02400112

Fractures, Open Surgical Wound Infection

TERMINATED PHASE4

Powdered Intrawound Vancomycin in Open Fractures Trial

NCT06504992

Open Fracture Trauma Infection, Surgical Site +4 more

NOT_YET_RECRUITING PHASE4

LocalVancomycinPowderToPreventPeriprostheticJointInfection.

NCT05697965

Arthroplasty Complications Periprosthetic Fracture of Hip

UNKNOWN PHASE2

Evaluating the Efficacy and Safety of Intra-wound Vancomycin Powder in High Risk Patients

NCT03839914

Spinal Deformity Trauma Spinal Tumor +1 more

RECRUITING NA

Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients

NCT01566422

Surgical Site Infection

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Aim: Compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder.

Primary Hypothesis: The proportion of deep surgical site infections will be lower for patients treated with local Vancomycin powder.

Secondary Aim #1: Compare antibiotic sensitivities of the bacteria in the patients who develop deep surgical site infections in study patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder.

Hypothesis 1: In the patients who develop infections, the antibiotic sensitivity profiles between patients treated with local Vancomycin powder will be non-inferior to those treated without local Vancomycin powder.

Secondary Aim #2: Build and validate a risk prediction model for the development of deep surgical site infections in patients treated without local Vancomycin powder. (b) Explore whether the effect of local Vancomycin powder is modified by the predicted risk of infection.

Hypothesis 2: Patient (e.g. medical co-morbidities) and injury (e.g open fractures) factors will be highly predictive of infection risk.

Hypothesis 3: Patients with higher predictive risk will experience greater benefit from local antibiotics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Operative Surgical Site Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vancomycin Antibotic Powder

Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.

In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.

Group Type EXPERIMENTAL

Vancomycin antibiotic powder

Intervention Type DRUG

At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.

Standard of Care

Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vancomycin antibiotic powder

At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All "high energy" tibial plateau fractures treated operatively with plate and screw fixation.
* We define "high energy" tibial plateau fractures as patients who are either:

* Initially treated with an external fixation (with or without limited internal fixation) and treated definitively more than 3 days later after swelling has resolved.
* Any open type I, II, or IIIA fracture, regardless of timing of definitive treatment.
* Any tibial plateau fracture associated with ipsilateral leg compartment syndrome fasciotomy wounds.
* All "high energy" pilon (distal tibial plafond) fractures treated operatively with plate and screw fixation. We define "high energy" pilon fractures as patients who are either:

* Initially treated with an external fixation (with or without fibula fixation or limited internal fixation) and treated definitively more than 3 days later after swelling has resolved.
* Any open type I, II, or IIIA fracture, regardless of timing of definitive treatment.
* Any tibial pilon fracture associated with ipsilateral leg compartment syndrome fasciotomy wounds.
* Ages 18 to 80 years
* Patients may have co-existing non-tibial infection, with or without antibiotic treatment.
* Patients may have risk factors for infection including diabetes, immunosuppression from steroids or other medications, HIV, or other infections.
* Patients may have a head injury
* Patients may have a portion of the fixation (e.g. fibula fixation in pilon or percutaneous screws across a tibial plateau fracture) prior to definitive plate fixation, at the initial surgery before randomization.
* Patients may have other orthopedic and non-orthopaedic injuries.
* Patients may have pre-existing musculoskeletal injuries, be non ambulators, or have spinal cord injuries.
* Women and minorities are included

Exclusion Criteria

* The study injury: tibial plateau, pilon, is already infected at time of study enrollment.
* Patient speaks neither English nor Spanish.
* Patients who have already had definitive fixation prior to enrollment in the study.
* Severe problems with maintaining follow-up (e.g. patients who are homeless at the time of injury or those how are intellectually challenged without adequate family support).
* Patients with allergies, drug administration reactions, or other sensitivities to Vancomycin (such as a history of Redman's Syndrome).
* Pregnancy.
* The study injury is a type IIIB or IIIC open fracture.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No